Benefit with cardiac myosin activator in HFrEF - PACE-CME

Benefit with cardiac myosin activator in HFrEF

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients
Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients
AHA 2020
Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients
- Deepak Bhatt, MD
Strengths and limitations of one-month DAPT trial
Strengths and limitations of one-month DAPT trial
AHA 2020
Strengths and limitations of one-month DAPT trial
- Róisín Colleran, MD
Comparing P2Y12 inhibitors in patients undergoing elective PCI
Comparing P2Y12 inhibitors in patients undergoing elective PCI
AHA 2020
Comparing P2Y12 inhibitors in patients undergoing elective PCI
- Jur ten Berg, MD, PhD
What is the value of a polypill with or without aspirin?
What is the value of a polypill with or without aspirin?
AHA 2020
What is the value of a polypill with or without aspirin?
- Prof. Salim Yusuf